Kazia Therapeutics (KZIA) CEO discloses multi-million share option stakes on Form 3
Rhea-AI Filing Summary
Kazia Therapeutics filed an initial ownership report for Chief Executive Officer John E. Friend II, showing he holds several option awards rather than recent market trades. These options give him the right to buy both American Depositary Shares (ADSs) and ordinary shares at preset prices before their expiration dates.
He holds ADS options over 30,000 ADSs at an exercise price of $0.3770 per ADS expiring on July 22, 2027, and over 500,000 ADSs at $6.5800 per ADS expiring on July 3, 2027. He also holds ordinary share options over 3,000,000 shares at $0.1323 per share expiring on May 3, 2027, and 1,000,000 ordinary shares at $0.1061 per share expiring on March 3, 2027.
Footnotes explain that these options vest in quarterly or annual installments starting between 2023 and 2025, subject to his continued service, and that exercise prices are reported in U.S. dollars based on a stated AUD/USD exchange rate. No purchases or sales occurred; this filing mainly outlines his existing equity-based compensation.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | American Depositary Share Option (Right to Buy) | -- | -- | -- |
| holding | American Depositary Share Option (Right to Buy) | -- | -- | -- |
| holding | Ordinary Shares Option (Right to Buy) | -- | -- | -- |
| holding | Ordinary Shares Option (Right to Buy) | -- | -- | -- |
Footnotes (1)
- The American Depositary Shares ("ADSs") subject to the option ("ADS option") vest in equal quarterly installments over three years beginning on April 22, 2024, subject to the Reporting Person's continuous service relationship with the Issuer through each applicable vesting date. The ADS option was granted on July 22, 2024. Each ADS option is convertible into ADSs upon exercise. Each ADS may be represented by 500 ordinary shares of the Issuer, no par per share (the "Ordinary Shares"), at any time, upon the holder's election to surrender the ADSs and withdraw the respective number of Ordinary Shares. The ADSs have no expiration date. The ADSs subject to the ADS option vest in three equal annual installments beginning on July 3, 2025, subject to the Reporting Person's continuous service relationship with the Issuer through each applicable vesting date. The ADS option was granted on July 3, 2025. The Ordinary Shares subject to the option ("OS option") vest in three equal annual installments beginning on May 3, 2023, subject to the Reporting Person's continuous service relationship with the Issuer through each applicable vesting date. The OS option was granted on May 3, 2023. The exercise price is reported in U.S. dollars and reflects the conversion from AUD to USD at an exchange rate of 0.7075 USD per 1.00 AUD as of March 18, 2026. The Ordinary Shares subject to the OS option vest in two equal annual installments beginning on March 3, 2023, subject to the Reporting Person's continuous service relationship with the Issuer through each applicable vesting date. The OS option was granted on March 3, 2023.
